MedicaidCoverageMedium impact
Tzield® (Teplizumab-Mzwv)
UnitedHealthcare·Endocrinology, Pediatrics, Internal Medicine·Medical Benefit Drug Policy
Effective date
Oct 1, 2026
We identified it
Sep 2, 2026
Summary
UnitedHealthcare Community Plan (Medicaid) has issued a revised medical benefit drug policy for Tzield® (Teplizumab-Mzwv) effective October 1, 2026. The policy document title and category indicate this is a coverage and/or billing guidance update for this pharmaceutical product, but the specific policy details are not provided in the source material shared.
Action Required
By September 15, 2026: Obtain and review the complete Tzield® (Teplizumab-Mzwv) policy document from the UnitedHealthcare Community Plan Medical Policy Update Bulletin (September 2026) at the provided URL. Billing team must: (1) Identify specific HCPCS codes for teplizumab administration and infusion; (2) Determine prior authorization requirements, if any; (3) Confirm coverage criteria and medical necessity documentation requirements; (4) Update billing system and encounter templates accordingly. Notify providers of any changes to coding or authorization workflows. Failure to implement policy requirements by the October 1, 2026 effective date may result in claim denials or payment delays.